Denosumab Ascend (denosumab)

Where it stands

Denosumab Ascend (denosumab) is authorised in the EU. Ascend GmbH holds the marketing authorisation. The CHMP adopted a positive opinion on 25 June 2026, and the European Commission decision approving the product followed on 28 August 2026, about nine weeks later. That interval is consistent with the usual Commission decision-making process after a CHMP opinion.

The authorised indications are two. The first is prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone. The second is treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable, or where surgical resection is likely to cause severe morbidity.

The records do not cover launch dates, member-state availability, presentations or strengths.

Regulatory pathway and designations

The product carries a Biosimilar designation. In the EU this means the CHMP assessed it against an authorised reference biological medicine, with the evidence package built around demonstrating similarity in quality, biological activity, safety and efficacy. The records confirm the designation but do not name the reference product or describe the comparability data. They also give no detail on the assessment itself, such as questions raised or the clinical programme.

The product is also flagged for Additional monitoring. This is a regulatory status, not a conclusion that a safety problem exists. The records give no reason for it, so none should be inferred.

The records list other denosumab products: Bildyos, Jubereq, Yaxwer, Prolia and Vevzuo (all EU, Authorised), and Enoby (US, Approved). They do not say how these relate to Denosumab Ascend in sponsor, reference product or indication. Prolia is listed as the same substance, but this product's indications are oncology-related, so scope should be checked product by product in each Summary of Product Characteristics.

Safety and pharmacovigilance

The only safety-related information in the records is the Additional monitoring designation. Products with this status are marked in the product information, usually with an inverted black triangle, and healthcare professionals and patients are encouraged to report any suspected adverse reactions.

The records contain no safety data, risk management plan content, post-authorisation commitments, or conditions of the marketing authorisation. This analysis therefore cannot describe the product's specific risks or risk-minimisation measures. Readers should consult the EPAR and the product information for these.

What to watch

The records give no forward-looking milestones. Practical points to follow include publication of the EPAR and final product information, national launch timing, and how Denosumab Ascend positions itself among the other authorised EU denosumab products listed. The records do not provide any of these.

Pharmacovigilance is also worth tracking, particularly any periodic safety reporting or product information updates while the additional monitoring status remains. The records do not say when the status might be reviewed. They also do not state whether the US-approved Enoby has any connection to this EU authorisation, so none should be assumed.